# OnCo record cardiotoxicity (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/cardiotoxicity/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "cardiotoxicity" ;
  schema:name "Cardiotoxicity (LVEF decline, cardiomyopathy)"@en ;
  schema:alternateName "cardiac toxicity"@en, "cardiotoxic"@en, "cardiomyopathy"@en, "heart failure"@en, "LVEF"@en, "left ventricular ejection fraction"@en, "ejection fraction"@en, "LVEF decline"@en, "asymptomatic LVEF decline"@en, "echocardiography"@en, "echocardiogram"@en, "MUGA"@en, "cardiac monitoring"@en, "cardiac surveillance"@en, "cardioprotection"@en, "cardioprotective"@en, "anthracycline cardiotoxicity"@en, "cardiovascular toxicity"@en, "cardiovascular events"@en, "arterial hypertension"@en, "arrhythmia"@en, "atrial fibrillation"@en ;
  schema:description "Heart damage from cancer treatment: anthracyclines weaken the heart muscle permanently in a dose-related way, trastuzumab does so reversibly, and some kinase inhibitors raise blood pressure or disturb rhythm. Heart function (LVEF) is monitored by ultrasound during treatment."@en ;
  schema:url <https://onco.cc/terms/cardiotoxicity/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Cardiotoxicity> ;
  schema:citation <https://en.wikipedia.org/wiki/Cardiotoxicity>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/carboplatin-paclitaxel-ec-pembrolizumab>, <https://doi.org/10.1001/jamainternmed.2015.1180>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/late-effects-lymphoma-treatment> ;
  onco:related <https://onco.cc/terms/anthracycline/>, <https://onco.cc/terms/myocarditis/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/qt-prolongation/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/cardio-oncology/> ;
  onco:drugs <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/ibrutinib/> .